Protagonist Therapeutics, Inc 8-K

What Happened

• Protagonist Therapeutics, Inc. announced that at its Annual Meeting stockholders approved a new 2026 Equity Incentive Plan that replaces the 2016 Plan. The 2026 Plan allows issuance of up to (A) the shares remaining under the 2016 Plan as of June 17, 2026 plus 650,000 newly authorized shares and (B) shares that return to the company from outstanding 2016 Plan awards that expire, are forfeited, reacquired, or are withheld for taxes or to satisfy exercise/purchase prices. The plan permits stock options, stock appreciation rights, restricted stock/RSUs and other stock-based awards, including performance-based awards. A copy of the 2026 Plan was filed as Exhibit 10.1 to the Form 8-K (filed June 18, 2026).
• At the same meeting stockholders elected two Class I directors — Dinesh V. Patel, Ph.D., and Lewis T. “Rusty” Williams, M.D., Ph.D. — and voted on compensation and auditor matters.

Key Details

• 2026 Plan: adds 650,000 newly authorized shares plus available remainder under the 2016 Plan and recaptured shares from forfeitures/returns.
• Director election votes: Dinesh V. Patel — For: 48,714,702; Withheld: 7,875,311; Broker Non-Votes: 2,819,234. Lewis T. Williams — For: 45,371,193; Withheld: 11,218,820; Broker Non-Votes: 2,819,234.
• Say-on-pay (non-binding) approved: For: 53,412,559; Against: 3,164,702; Abstentions: 12,752; Broker Non-Votes: 2,819,234.
• Auditor ratification approved (Ernst & Young LLP): For: 59,371,487; Against: 28,221; Abstentions: 9,539.
• Vote to approve 2026 Equity Incentive Plan: For: 47,745,562; Against: 8,826,703; Abstentions: 17,748; Broker Non-Votes: 2,819,234.

Why It Matters

• The 2026 Equity Incentive Plan gives the company flexibility to grant equity compensation (options, RSUs, performance awards) to employees, directors and consultants — a common tool to attract and retain talent. That can lead to future dilution depending on the number of awards granted, so investors should monitor grant activity and outstanding share counts in future filings.
• Re-election of the two Class I directors and ratification of Ernst & Young provide continuity in governance and financial oversight. The advisory approval of executive compensation indicates stockholder support for current pay practices (non-binding).
• No financial results or operational changes were reported in this filing; the main takeaways are governance and compensation-plan updates.